Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21947593 | 1.00 | SLC7A5 (0.54) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL3770254 | 1.00 | SLC7A5 (0.54) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL28637433 | 0.84 | SLC7A5 (0.54) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL30547274 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL5869551 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL30831490 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL1816260 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL2580149 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL31505896 | 0.84 | GRIA2 (0.56) | SLC7A5ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL19699296 | 0.84 | SLC7A5 (0.54) | SLC7A5ALDH1A1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103619336-B | Sanglifehrin derivatives and process for preparing the same | 纽洛维弗制药有限公司 | 2017-10-27 | — | — | CN | disclosed |
| CN-107090476-A | Sanglifehrin derivatives and preparation method thereof | 纽洛维弗制药有限公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-103619336-A | Sanglifehrin derivatives and process for preparing the same | BIOTICA TECH LTD | 2014-03-05 | — | — | CN | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| US-5874472-A | Aminoacid derivatives as no synthase inhibitors | GLAXO WELLCOME INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0705257-B1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | WELLCOME FOUND (GB) | 1998-03-11 | — | — | EP | disclosed |
| EP-0705257-A1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000505-A1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | SLC7A5 1155/4885ALDH1A1 1388/4885NOS3 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.